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Abstract
The vitamin K-dependent carboxylase is an integral membrane protein which is required for the
post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have
suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In the present study, we
identified the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping
analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the
N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant
carboxylase to migrate faster in SDS-PAGE gel analyses, adding further evidence that these sites
are glycosylated. In addition, the mutation studies identified N525, a site not recoverable by mass
spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at
N570 is glycosylated only if all the five natural glycosylation sites are simultaneously mutated.
Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by eliminating the
functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation
or epoxidation activity when the small pentapeptide FLEEL was used as substrate, suggesting that
N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when
site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting
carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential
for carboxylase enzymatic activity but it is important for protein folding and stability.
The vitamin K-dependent carboxylase, also known as gamma-glutamyl carboxylase
(GGCX)1, is an integral membrane protein of the endoplasmic reticulum. It catalyzes the
post-translational modification of specific glutamic acid residues of vitamin K-dependent
proteins to γ-carboxyglutamic acid residues. This post-translational modification is critical
for the biological functions of the vitamin K-dependent proteins involved in blood
coagulation, bone metabolism, signal transduction, and cell proliferation (1-3). In addition to
its vitamin K-dependent substrate, the carboxylation reaction, which occurs in the lumen of
the ER (4, 5), requires the co-substrates carbon dioxide, oxygen, and vitamin K
hydroquinone. During the process of carboxylation, the γ-proton of the glutamic acid is
abstracted, followed by the addition of carbon dioxide (6-9). Concomitant with
carboxylation, vitamin K hydroquinone is oxidized to vitamin K epoxide which must be
converted back to vitamin K by the enzyme vitamin K epoxide reductase, thus completing
the vitamin K cycle (1, 10). The formation of vitamin K epoxide during the carboxylation
reaction has been called an epoxidation reaction (9, 11, 12). It was suggested that an
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oxygenated intermediate of vitamin K produced by GGCX activates the γ-carbon of a
glutamate and then yields vitamin K epoxide (6, 13).
It has been reported that GGCX binds to lectin suggesting that it is a glycoprotein (14, 15).
Moreover, Endoglycosidase H treatment of GGCX purified from bovine liver indicates that
it is an N-linked glycoprotein (16). N-linked glycosylation occurs at an asparagine residue in
the canonical sequence NXS/T (glycosylation sequon) where X can be any residue except
proline (17, 18). It is the most prevalent co-translational modification that occurs in the
lumen of the ER. N-linked glycosylation plays an important role in maintaining protein
stability, modulating protein-protein interactions, and protein membrane targeting (19-21).
In addition, alterations of the sugar chain of glycoproteins are associated with various
diseases such as cancer (22-24).
In human GGCX, there are 9 potential N-linked glycosylation sequons. A study of the
membrane topology of GGCX (25) demonstrated that all of the potential glycosylation sites
are located in the ER lumen where the glycosylation enzymes occur. GGCX migrates as a
94 kDa protein in SDS-PAGE (26). This is about 6 kDa greater than expected based upon its
predicted amino acid sequence (87.6 kDa) (27). Results of sedimentation equilibrium
proposed that glycosylation of GGCX causes a molecular weight increase of 12.8 kDa (28).
These results support the notion that GGCX is a glycoprotein with multiple sites being
glycosylated. However, the number of potential glycosylation sites that are actually
modified, as well as the importance of glycosylation on GGCX activity and stability, are still
unknown. In this study, we used mass spectrometry combined with site-directed
mutagenesis to identify the glycosylation sites in human GGCX. We also examined the
effect of glycosylation on carboxylation and epoxidation activity.
EXPERIMENTAL PROCEDURES
Materials
All chemicals were reagent grade. CHAPS, CNBr, and α-cyano-4-hydroxysuccinnamic acid
were obtained from Sigma (St. Louis, MO). 18O water (Normalized 96.5% atom% 18O) was
from Isotec (Milwaukee, WI). Vitamin K1(20) (10 mg/mL) was from Abbott Laboratories
(Chicago, IL). Vitamin K1(25) was from GLsynthesis Inc. (Worcester, MA). NaH14CO3
(specific activity, 54 mCi/mmol) was from ICN Pharmaceuticals, Inc. (Costa Mesa, CA).
Aprotinin, pepstatin A, trypsin (modified, sequencing grade), chymotrypsin (sequencing
grade), and endoproteinase Glu-C (sequencing grade) were purchased from Roche
Molecular Biochemicals (Indianapolis, IN). Pentapeptide FLEEL and protease inhibitor H-
D-Phe-Pro-Arg chloromethylketone were from Bachem (King of Prussia, PA). 1,2-Dioleoyl-
sn-Glycero-3-Phosphocholine was from Avanti (Alabaster, AL). The propeptide of proFIX
and the fluorescein-labeled consensus propeptide were chemically synthesized and purified
by Chiron Mimotopes (Clayton, Victoria, Australia). Restriction enzymes and PNGase F
were from New England Biolab (Beverly, MA). Bac-to-Bac baculovirus expression system,
Bis-Tris NuPAGE gel, protein standards, and oligonucleotides were from Invitrogen Life
Technologies (Carlsbad, CA). Pfu Turbo DNA polymerase was from Stratagene (La Jolla,
CA). Anti-HPC4 antibody coupled Sepharose resin was kindly provided by Dr. Charles
Esmon (Cardiovascular Biology Research Program, Oklahoma Medical Research
Foundation, Oklahoma City, Oklahoma 73104, USA).
Expression and Purification of GGCX in Insect Cells
Wild-type human GGCX cDNA with a HPC4 tag (EDQVDPRLIDGK) at the carboxyl
terminus (29) was engineered into the baculovirus expression vector pFastBac1 by BamH I
and EcoR I sites. The resulting plasmid, pFastBac1-GGCX-HPC4, was transformed into E.
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coli. strain DH10Bac and the recombinant bacmid was screened by blue/white selection
according to the manufacturer's instructions (Invitrogen). Recombinant baculovirus was
obtained by Cellfectin induced infection of Sf9 cells and screened by GGCX activity assay
of the cell lysate. Expression of GGCX was performed by infection of 2 × 106/mL Sf9 cells
with the recombinant virus at a multiplicity of infection of 1. Cells were collected after 48 h
of infection, and the expressed GGCX was purified by affinity chromatography using anti-
HPC4 antibody-coupled Sepharose resin as previously described (29).
Limited Trypsinization and PNGase F Digestion of GGCX
Limited trypsin digestion of GGCX in the presence of propeptide was performed as
previously described (16). Cleavage was accomplished on ice in the presence of 5 μM
proFIX and the reaction was stopped by the addition of H-D-Phe-Pro-Arg
chloromethylketone and aprotinin to a final concentration of 1.6 μM. To examine the N-
glycosylation modification, intact and/or trypsinized GGCX were incubated with 100 units/
mL PNGase F in 50mM sodium phosphate (pH 7.5) at 4°C for 16 h. PNGase F treated and
non-treated samples were fractionated by 10% Bis-Tris NuPAGE and visualized by silver
staining.
In-gel Protease Digestion and Deglycosylation of GGCX for Mass Spectrometry Analysis
Glycoproteins often yield poor peptide maps for mass spectrometry analysis because the
oligosaccharides can effectively shield proteolytic cleavage sites (30). Therefore, with the
exception of the experiment using 18O labeling, freshly purified GGCX was deglycosylated
before being subjected to in-gel protease digestion (31). After deglycosylation, GGCX
samples were fractionated by 10% SDS-PAGE and protein bands were visualized by
Coomassie staining. The GGCX band was excised, and the gel pieces were treated as
described previously (31). The dry gel pieces were re-hydrated by the addition of (10 ng/μL)
protease (trypsin, Endoproteinase Glu-C, or chymotrypsin) in 25 mM NH4HCO3 solution
and incubated on ice for 30 minutes. After re-hydration, the protease solution was removed
and the gel pieces were covered with an overlay of 20 μL of 25 mM NH4HCO3 solution.
The gel pieces remained immersed throughout the digestion. The protein was digested
overnight at 30°C without agitation. Digestion supernatants were directly pooled for mass
spectrometry analyses.
The combined tryptic and CNBr cleavage was performed as described previously (32).
Briefly, after tryptic digestion, the gel pieces were dried directly in the SpeedVac. These
dried gel pieces were washed and dehydrated by acetonitrile. CNBr cleavage was started by
the addition of sufficient CNBr solution in 70% TFA and the reaction was carried out
overnight in the dark at room temperature. After collection of the supernatant, the peptides
were extracted twice by sonication for 5 minutes in 30 μL of 60% acetonitrile with 1% TFA.
The overlay and extracts were pooled and dried in a SpeedVac. The sample was dissolved in
5 μL of 40% acetonitrile with 0.1% TFA for mass spectrometry analysis.
To further confirm the glycopeptides identified by MALDI-TOF MS, the glycosylation sites
of GGCX were labeled by 18O through in-gel PNGase F deglycosylation as described
previously (33). Briefly, affinity purified GGCX was applied directly to SDS-PAGE without
PNGase F treatment and the Coomassie blue stained GGCX band was excised and treated as
described above. The dry gel pieces were swollen in 50mM sodium phosphate (pH 7.5) with
100 units/mL PNGase F and 50% H 182O. The reaction was incubated overnight at 37°C.
PNGase F was removed prior to proteolysis by washing the gel pieces with 0.1% SDS in
100 mM NH4HCO3 (four changes, 1 h per change). All washings were discarded and SDS
was removed from the gel pieces by incubation with methanol/water/acetic acid (50:45:5,
v:v:v) for 30 minutes followed by three washes with 50% acetonitrile in 100 mM
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NH4HCO3. The resulting gel plugs were dried in a SpeedVac. In-gel trypsin digestion of
the 18O labeled protein samples was carried out as described above.
Identification of N-glycosylation Sites of GGCX by Mass Spectrometry
Protease digested samples were applied to MALDI-TOF MS and Q-TOF MS for identifying
the N-glycosylation sites of human GGCX. For MALDI-TOF MS, 0.3 μL of the above
protease digested sample and 0.3 μL of 10 mg/mL 1-cyano-4-hydroxysuccinnamic acid in
50% acetonitrile containing 0.1% TFA (v/v) were deposited on the target plate and air-dried.
MALDI-TOF mass spectra were recorded with an ABI 4700 Proteomics Analyzer (Applied
Biosystems, Foster City, CA) MALDI-TOF/TOF mass spectrometer. A frequency-tripled
Nd:YAG laser ionized samples at a pulse frequency of 200 Hz with its power adjusted
between 15 and 30 μJ, depending on the sample. Laboratory air was used as the collision gas
and the collision cell vacuum pressure was 7~9 × 10–7 Torr. MALDI-TOF data from tryptic
digests were calibrated with auto-proteolytic peaks (internal standards) and mass errors were
less than 20 ppm. The mass range for TOF MS scan functions was set to m/z 500 to 4000.
TOF MS/MS scan functions were calibrated externally against the fragments of either
angiotensin I or adrenocorticotropic hormone fragment 18~39 depending upon the precursor
mass. The mass accuracy of CID data was typically better than 50 ppm.
ESI analyses of proteolytic fragments were conducted using nanoelectrospray LC-MS/MS
on a Q-TOF API-US instrumental platform (Waters Corporation). The PepMap dC18, 5 μm,
0.075 × 100 mm column (LCPackings Corporation) was used for peptide separation. On the
Q-TOF, the intensity criteria of signal to noise for MS to MSMS switch is set to 10, whereas
the threshold for MSMS to MS switch is set to above 3500 Counts/s. Ions in charge states of
2+, 3+, and 4+ detected in the survey scan were selected for MSMS.
Raw data files from Q-TOF instrument are processed with Mascot Distiller (Version 1.1.1.0,
Matrix Science, London) without smoothing using charge states determined from the MS
scan. The resulting centroid files were searched against NCBI nr database using Protein
Prospector. The mass tolerance of the precursor peptide ion was fixed at 200 ppm whereas
the mass tolerance for the MS/MS fragment ions was set to 0.5 Da.
Mutation of the N-glycosylation Sites in GGCX by Site-Directed Mutagenesis
To remove the N-glycosylation sites in GGCX, the asparagine (N) residue within the
canonical glycosylation sequence NXS/T was replaced with a glutamine (Q) residue by site-
directed mutagenesis using sequence overlap extension PCR. The vector pFastBac1-GGCX-
HPC4 was used as the template. The four N-glycosylation sites identified by mass
spectrometry were removed one by one by changing asparagine to glutamine. To verify
whether asparagine residues at position 389, 525, and 570 are glycosylated in vivo, we
changed each of these three asparagines to glutamine individually in the GGCX mutant
GGCX605 that already had the four confirmed glycosylation sites removed. To determine
whether asparagine 389 or 570 is glycosylated when all the five natural glycosylation sites
were removed from GGCX, these two asparagines were changed to glutamine individually
in the GGCX mutant GGCX525 that had all the five natural glycosylation sites removed. The
resulting GGCX mutants are shown in Table 1. All the final constructs were fully sequenced
by the Genome Analysis Facility of the University of North Carolina at Chapel Hill to
ensure fidelity and proper introduction of the mutations. All of the GGCX mutants were
expressed and affinity purified from Sf9 cells as described above.
GGCX Activity Assays
GGCX activity was determined by the incorporation of 14CO2 into the pentapeptide
substrate FLEEL in the presence of propeptide. For assays of cell lysates, 10 μL of cell
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pellet was mixed with 105 μL of lysis buffer (final concentrations-0.5% CHAPS, 25 mM
Tris-HCl (pH 7.5), 500 mM NaCl, 4 μM proFIX, and 1.25 mM FLEEL). Samples were
placed on ice for 30 minutes with occasional vortexing. The carboxylation reaction was
started by the addition of 10 μL of an ice-cold mix of NaH14CO3 (40 μCi/mL final
concentration) and vitamin K hydroquinone (222 μM final concentration) to bring the
volume to 125 μL. The reaction mix was immediately transferred to a 20 °C water bath and
incubated for 30 minutes. The reactions were terminated by the addition of 1 mL 5%
trichloroacetic acid, and the amount of 14CO2 incorporation was determined as described
(29). The assays for purified GGCX were performed at a final concentration of 25 mM Tris-
HCl (pH 7.5), 500 mM NaCl, 0.8 M (NH4)2SO4, 0.12% 1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine, 0.28% CHAPS, 4 μM proFIX, and 1.25 mM FLEEL; the carboxylation
reaction was carried out as above. The concentration of active GGCX was determined from
the fraction of protein binding to the fluorescein-labeled consensus propeptide by
fluorescence anisotropy as described previously (28).
Vitamin K Epoxidation Activity Assay
Vitamin K epoxidation activity was determined by quantitation of the vitamin K epoxide
formed during the carboxylation of FLEEL as described above, except that unlabeled
NaHCO3 was used. The reactions were terminated by the addition of 500μL isopropanol.
The mixture was extracted with 500μL hexane containing 2.52 μM vitamin K1(25) as an
internal standard. Vitamin K epoxide formation was quantitated by HPLC (34) on a C18
column (4.6×250 mm, Vydac, Hesperia, CA) with an isocratic elution. The mobile phase
was acetonitrile:isopropanol:water (100:7:2, v:v:v), flow rate was 2.00 mL/min, and the UV
detection wavelength was 248 nm.
RESULTS
N-glycosylation Sites of GGCX Are Located on the Carboxyl-terminal Tryptic Fragment
There are 9 potential glycosylation sites in GGCX. These sequons are at asparagine residues
159, 389, 459, 525, 550, 570, 605, 627, and 735. To re-confirm that human GGCX is a N-
linked glycoprotein, affinity purified recombinant human GGCX was treated with PNGase
F, an enzyme that removes carbohydrates from asparagine residues. Figure 1 demonstrates
that PNGase F treated GGCX (lane 2) migrates faster than the untreated sample (lane 1) in
SDS-PAGE analysis indicating that GGCX is an N-linked glycoprotein. Previous work from
our laboratory showed that limited trypsin digestion of GGCX results in a disulfide-linked
30 kDa amino-terminal and 60 kDa carboxyl-terminal fragments (16) (Figure 1, lane 3).
Figure 1 (lane 4) shows that only the 60 kDa carboxyl-terminal tryptic fragment is sensitive
to PNGase F digestion indicating, in agreement with our previous report (16), that N-linked
glycosylation occurs only on the 60 kDa carboxyl-terminal tryptic fragment of GGCX.
Asparagine 159 is the only potential glycosylation site in the 30 kDa amino-terminal tryptic
fragment and these results indicate that it is not glycosylated in vivo.
Identification of the N-linked Glycosylation Site in GGCX by Mass Spectrometry
Removal of the oligosaccharides from asparagines by PNGase F converts the asparagine
(114 Da) to aspartate (115 Da). This 1-Da mass increase of the deglycosylated peptide
relative to the corresponding nonglycosylated peptide has been widely used for identifying
glycoproteins using MALDI-TOF MS (35-37). In this study, we used this 1-Da shift to
identify the N-linked glycosylation sites in GGCX. Table 2 summarizes the proteolytic
glycopeptides detected by mass spectrometry. Six glycopeptides containing glycosylation
sites N459, N605, and N627 of human GGCX were recovered by MALDI-TOF based on the
1-Da mass shift (Table 2, top panel). Using Q-TOF MS analyses of proteolytically treated
GGCX, we identified another glycosylation site at N550 (Table 2, bottom panel). Due to the
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hydrophobic characteristics of transmembrane peptides and the lack of appropriate protease
sites to generate the appropriate size peptides for mass spectrometry analysis, we were
unable to recover peptides containing the potential glycosylation sites N389, N525, and
N570.
18O-labeling of the Asparagine Residue within the N-glycosylation Sequon
To further confirm the identity of the sites demonstrated above, we performed in-gel
deglycosylation of GGCX by PNGase F in the presence of 50% 18O water as described in
Experimental Procedures. When hydrolysis occurs, about 50% of the resulting aspartic acid
residues will be labeled with 18O. This proteolytically derived deglycosylated peptide
incorporating 18O can be recognized in MALDI-TOF mass spectrum as doublets peaks with
a characteristic 2-Da spacing (33). Figure 2 shows the MALDI-TOF spectrum of 18O-
labeled and non-labeled tryptic glycopeptides of GGCX at m/z 2433.29 and 2690.42 as listed
in Table 2. Doublet peaks differing by 2-Da appear in the 18O-labeled sample (Figure 2 B
and D) indicating that these two peptides are glycopeptides and site N627 is a functional
glycosylation site in vivo. Using this 18O-labeling technology, all of the tryptic peptides
previously identified as glycosylated were confirmed (Data not shown).
Tandem Mass Spectrometry Analysis of the Proteolytic Glycopeptides
Further proof that the identified peptides are glycopeptides is provided by sequencing the
precursor ions of the abundant glycopeptide by tandem mass spectrometry. We isolated
precursor peptides using the timed ion selector. The selected peptides were subjected to
collision-induced dissociation for amino acid sequencing. The most commonly observed
product ions resulting from collision-induced dissociation belong to the y-type ion series,
which results from backbone cleavage of the C–N amide linkage with the charge retained on
the carboxyl-terminal fragments. The product ions are numbered according to the cleavage
site from the carboxyl-terminal end. Figure 3 shows an example tandem mass spectrum of
the trypsin/CNBr digested deglycosylated peptide at m/z 2617.34. This spectrum reveals a
series of y-ions from the corresponding peptide YVYVNTTELALEQDLAYLQELK of
wild-type GGCX. The mass difference between the y18 and y17 ions is 115 units, which
corresponds to an aspartic acid residue rather than an asparagine residue (114) at position
605 in wild-type GGCX sequence, as labeled in Figure 3. This asparagine to aspartic acid
conversion is due to the PNGase F deglycosylation which further supports the above
assignment of the glycopeptides. In addition to the y ions, we also observed the b-ion series
in the spectrum which corresponds to the same cleavage of the C–N amide linkage by
collision-induced dissociation but with the charge retained on the N-terminal fragments.
This result provides still further support that N605 is glycosylated. Sequencing of the
abundant deglycosylated peptide at m/z 2690.42 and m/z 2433.29 also indicate that
asparagine 627 is glycosylated (Data not shown). Because of the low abundance of other
glycopeptides, we were unable to obtain satisfactory sequencing results that might further
substantiate glycosylation of site N459.
Removal of the N-glycosylation Sites of GGCX by Site-Directed Mutagenesis
Together, the above results demonstrate that four of the glycosylation sites in GGCX, N459,
N550, N605, and N627 are glycosylated during co-translational modification. However, we
were unable to recover peptides covering the remaining sites. Since N-glycosylation occurs
at asparagine residues within the canonical sequence of NX(S/T), changing asparagine to
glutamine (or another residue) will abolish glycosylation at the mutated site. The elimination
of one glycosylation site may reduce the protein molecular weight by as much as 3 kDa (19).
Therefore, if the glycosylation sites are modified, we expect the mutated proteins to migrate
differently in SDS-PAGE. Figure 4A shows SDS-PAGE analysis of the affinity purified
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GGCX mutants. Changing N459, N550, N605, or N627 (lane 2 to lane 5) to glutamine alters
the migration of GGCX on reducing SDS-PAGE. This result supports the mass spectrometry
results and indicates that eliminating the glycosylation sequon results in a measurable
change in migration of GGCX on reducing SDS-PAGE gels. However, treatment of
GGCX605 (with all 4 identified glycosylation sites removed) with PNGase F causes a further
increase of its mobility (Figure 4A, lane 6), suggesting that these four glycosylation sites are
not the only functional glycosylated sites in GGCX.
Identification of N-glycosylation Sites in GGCX by Site-Directed Mutagenesis and Gel-shift
Analysis
Results shown in Figure 4A (lane 6) suggest there is, in addition to the four sites identified
by MS, at least one additional glycosylation site in GGCX. It also shows that removal of a
genuine glycosylation site in GGCX causes a visible decrease in size detected by SDS-
PAGE. To further examine this question, we started with a GGCX molecule (GGCX605)
with the four confirmed glycosylation sites mutated to glutamine. To this mutated molecule
(GGCX605) were added mutations of N389Q, N525Q, and N570Q individually. Figure 4B
compares the migration difference among these affinity purified GGCX mutants by SDS-
PAGE analysis. As can be seen, GGCX389 (Figure 4B lane 2) and GGCX570 (Figure 4B lane
3) mutants have the same migration distance as GGCX605 (Figure 4B lane 1) suggesting that
sites N389 and N570 are not glycosylated in vivo. In contrast, the GGCX525 (Figure 4B lane
4) mutant migrates faster than GGCX605 indicating that N525 is utilized for the addition of
carbohydrate during co-translational modification. These results, together with the results of
mass spectrometry, suggest that there are five functional N-glycosylation sites in GGCX at
residues N459, N525, N550, N605, and N627.
Figure 4B (lane 5) also shows that the GGCX525 mutant, which has simultaneously removed
all five glycosylation sites, is still sensitive to PNGase F digestion. This result raises the
possibility that when all the natural glycosylation sites in GGCX are removed, an alternative
glycosylation site functions. To verify this, we changed asparagine to glutamine individually
at the two candidate sites, N389 and N570 in mutant GGCX525 yielding two mutants:
GGCX389/525 and GGCX570/525. As shown in Figure 4C, GGCX389/525 (lane 2) and
GGCX525 (lane 1) have the same migration distance and both of them migrate faster after
PNGase F digestion (lane 3 and 4). This result suggests that GGCX389/525 and GGCX525
have the same glycosylation status, and that site N389 did not serve as the proposed
alternative glycosylation site. Since GGCX389/525 mutant is sensitive to PNGase F digestion
and N570 is the only candidate glycosylation site in this mutant, we propose that site N570
is the alternative glycosylation site. In addition, we were unable to properly express and
purify the GGCX570/525 mutant due to a protein degradation problem. These results together
suggest that site N570 may serve as an alternative glycosylation site. When site N570 and all
the five natural glycosylation sites are removed (mutant GGCX570/525), GGCX apparently
can not fold correctly.
N-linked Glycosylation Is not Required for the Enzymatic Function of GGCX
To investigate whether the removal of glycosylation sites affects the enzymatic function of
GGCX, the specific carboxylation activity and epoxidation activity of GGCX variants were
examined. Results are summarized in Table 3. As can be seen, removal of the sugar moieties
from wild-type GGCX by PNGase F digestion only has a minor effect on either the FLEEL
carboxylation (91.5%) or vitamin K epoxidation (86%) activities compared with that of the
wild-type enzyme. GGCX mutants that have 1 to 4 glycosylation sites removed (GGCX459,
GGCX627, GGCX550, and GGCX605) have normal or even higher carboxylation and
epoxidation activity. In addition, simultaneous removal of all five natural glycosylation sites
(GGCX525) causes only a 30% reduction in carboxylation and epoxidation activity relative
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to that of the wild-type enzyme. Table 3 also shows that the ratios of vitamin K epoxidation
and CO2 incorporation of all these GGCX variants are between 1.4 and 2.4, which agrees
with the results of Sugiura et al (38). These results suggest that N-linked glycosylation is not
required for either the carboxylation or epoxidation activity of GGCX.
DISCUSSION
The goal of this study was to identify the N-linked glycosylation sites in GGCX and
determine the importance of this post-translational modification to GGCX structure and/or
function. Evidence that GGCX is a glycoprotein was published about 20 years ago (14).
However, the details of which GGCX glycosylation sequons are modified and how this
modification affects GGCX maturation and enzymatic function is still unknown.
According to our results, N159, the only potential glycosylation site in the 30 kDa tryptic
peptide, is not modified (Figure 1). This result is not surprising since according to our
membrane topology model, N159 is located immediately after the third transmembrane
domain (138-158) (Figure 5) (25). According to the “minimum glycosylation distance” rule
(39, 40), for efficient glycosylation, the minimum number of residues between the
glycosylation acceptor Asn and the lumenal end of a transmembrane segment is between 10
and 14 amino acids. Therefore, N159 would not be expected to be modified. This result then
lends further support to our topology model.
Our mass spectrometric studies identified 4 glycosylation sites in human GGCX: N459,
N550, N605, and N627. However, peptides containing the potential sites at N525, 389 and
570 were not recovered. To investigate the status of these sites, to confirm the sites
identified by MS, and to allow evaluation of the functional importance of the various sites,
we created a series of mutant GGCXs. The four sites identified by MS were confirmed by
our mutational studies (Figure 4A). In addition site N525 was glycosylated under normal
circumstances (Figure 4B). Therefore, there are five functional glycosylation sites in GGCX.
The results (Figure 4B) with all the five glycosylation sites, N459, 525, 550, 605 and 627,
changed to Q indicated that there was at least one additional site in GGCX. But this site is
only glycosylated when the five sites were mutated simultaneously. The only possibility for
this additional glycosylation site is residues 389 or 570. We have already shown that neither
of these sites is glycosylated in the mutant GGCX605 (Figure 4B). Results of SDS-PAGE
gel-shift experiments (Figure 4C) show that site N570 is modified when all five of the
natural glycosylation sequons are removed. This interpretation is derived from the result
with the GGCX mutant GGCX389/525, since the GGCX with 5 mutations plus N570Q
(GGCX570/525) is degraded. We do not know whether GGCX570/525 is targeted for
degradation in the cell or is degraded during purification. That N389 is not glycosylated in
addition to the results with N159, adds further support to our membrane topology model
since it too falls under the “minimum glycosylation distance” rule. N389 is 8 residues away
from the last transmembrane domain (361-381) (Figure 5) (25).
Thus, glycosylation of GGCX is essential for proper, stable structure formation. It is
generally accepted that one of the key roles of N-linked glycosylation is to promote proper
protein folding of glycoproteins. When glycosylation is blocked, many glycoproteins do not
fold correctly (19, 41). Proteins in non-native conformations fail to pass ER quality control
and are targeted for degradation (42). Our results (Table 3) show that when five of the
natural glycosylation sites are removed, even one alternative glycosylation site (N570) is
sufficient for GGCX to pass ER quality control and to form an active enzyme (GGCX525);
however, the GGCX with N570 mutated, as well as the 5 natural sites, is degraded. This
suggests that a minimum of one glycosylation site is necessary either for folding of GGCX
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or for its stability once folded. This effect does not appear to be a local effect on structure,
since the exact glycosylaion site seems unimportant. This indicates the global importance of
glycosylation for the overall structure of GGCX. Therefore, glycosylation is important for
proper folding or for GGCX to pass quality control.
Enzymatic removal of the glycan moiety from purified GGCX by PNGase F has little effect
on the carboxylation (91.5%) and epoxidation (86%) activity. So while glycans are essential
for protein stability and/or folding, no glycosylation is necessary for expression of
enzymatic activity. Interestingly, the mutant enzymes with one to four sites mutated,
retained similar or even higher enzymatic activities compared to those of the wild-type
enzyme. The GGCXs with 3 and 4 mutated glycosylation sites had almost two-fold higher
epoxidase activity than that of wild type GGCX.
The enzymatic removal of glycans yields an aspartic acid residue in place of asparagine.
This changes the charge character of the enzyme. In this case the polar non-charged sugars
are replaced by a negative charge. On the other hand, mutation to Q simply replaces the non-
charged polar sugars with a smaller non-charged polar glutamine. Thus, in the latter case the
change is steric in nature. The hypothesis of how the carboxylation reaction occurs suggests
that oxidation of vitamin K hydroquinone to vitamin K epoxide activates the removal of the
γ-proton from the glutamic acid of the substrate to form a carbanion intermediate (6, 13).
Then, a CO2 molecule attacks this carbanion intermediate to form the final product of γ-
carboxyglutamic acid. One interpretation of our results is that replacing the glycan with the
smaller Q side-chain may allow easier access to vitamin K by removing steric hindrance to
this hydrophobic substrate's binding. In contrast, the smaller substrate CO2 is not as
significantly affected by this change. This may explain why the epoxidation activity
increases proportionately more than carboxylation in the mutant GGCX relative to that of
wild type GGCX.
While our results suggest that N-linked glycosylation is not required for the enzymatic
function of GGCX, it is based on the carboxylation of the small pentapeptide substrate
FLEEL in the presence of a separate factor IX propeptide in the in vitro assay system. In
vivo, the natural substrates for GGCX are macromolecules of vitamin K-dependent proteins.
These proteins, especially the coagulation factors are also glycoproteins. It has been reported
that the glycans in the coagulation factors are important for protein-protein interaction
(43-45), and that the glycosylation modification occurs before post-translational
carboxylation modification (46). Therefore, it is possible that the glycans in GGCX play a
role in the carbohydrate interaction between GGCX and its natural glycoprotein substrates.
The principal binding site for coagulation factors to GGCX is their propeptide (47). It has
been reported that the propeptide binding site in GGCX is located in the region of residues
495-513 (48). As shown in Figure 5, three out of the five functional glycosylation sites
(N459, N525, N550) are close to this region in the primary structure of GGCX sequence.
Binding of the propeptide, which causes a conformational change in GGCX, may bring the
glycans of the substrate and enzyme into proximity and facilitate substrate binding, and thus,
the carboxylation reaction.
In conclusion, we have identified the N-linked glycosylation sites of GGCX by mass
spectrometry and site-directed mutagenesis. Our results suggest that there are five
glycosylation sites in GGCX at positions N459, N525, N550, N605, and N627. The
potential glycosylation site at N570 is not glycosylated under normal conditions, but it
serves as an alternative site for glycosylation when all the natural glycosylation sites are
eliminated. Even this one site ensures that the protein folds correctly. While glycosylation is
Tie et al. Page 9













important for GGCX folding and to prevent degradation, it is not required for GGCX
enzymatic function.
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Figure 1. PNGase F treatment of intact and trypsin nicked GGCX
A reducing NuPAGE silver-stained gel is depicted. Lane 1, intact wild-type GGCX; lane 2,
intact wild-type GGCX digested by PNGase F; lane 3, trypsin nicked wild-type GGCX; lane
4, trypsin nicked wild-type GGCX treated by PNGase F; lane 5, PNGase F.
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Figure 2. MALDI-TOF mass spectra of 18O-labeled and non-labeled deglycosylated peptides of
GGCX
Panel A, spectrum of deglycosylated tryptic peptide of GGCX at m/z 2433.29; Panel B,
spectrum of 18O labeled deglycosylated tryptic peptide of GGCX at m/z 2433.29; Panel C,
spectrum of deglycosylated tryptic peptide of GGCX at m/z 2690.42; Panel D, spectrum
of 18O labeled deglycosylated tryptic peptide of GGCX at m/z 2690.42.
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Figure 3. Tandem mass spectrum sequencing of the deglycosylated proteolytic peptides
Trypsin/CNBr digested deglycosylated peptide of GGCX at m/z 2617.34 was isolated using
a timed ion selector and subjected to collision-induced dissociation fragmentation for amino
acid sequencing. The observed y-type ions correspond to the backbone cleavage of the C-N
amide linkage with the charge retained in the carboxyl-terminal fragment and the b-type ions
correspond to the same cleavage with the charge retained in the amino-terminal fragment
were labeled. Conversion of asparagine (N605) to aspartic acid (D) due to PNGase F
deglycosylation of the glycopeptide was marked.
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Figure 4. Gel-shift analyses of GGCXs with mutations at the potential glycosylation sites
Reducing NuPAGE silver-stained gels are depicted. Panel A, Lane 1, wild-type GGCX;
lane 2, GGCX459 mutant GGCX; lane 3, GGCX627 mutant GGCX; lane 4, GGCX550
mutant GGCX; lane 5, GGCX605 mutant GGCX; lane 6, GGCX605 mutant GGCX treated
with PNGase F; lane 7, wild-type GGCX treated with PNGase F. Panel B, lane 1, GGCX605
mutant GGCX; lane 2, GGCX389 mutant GGCX; lane 3, GGCX570 mutant GGCX; lane 4,
GGCX525 mutant GGCX; lane 5, GGCX525 mutant GGCX treated with PNGase F; lane 6,
GGCX605 mutant GGCX treated with PNGase F. Panel C, lane 1, GGCX525 mutant GGCX;
lane 2, GGCX389/525 mutant GGCX; lane 3, GGCX525 mutant GGCX treated with PNGase
F; lane 4, GGCX389/525 mutant GGCX treated with PNGase F.
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Figure 5. Membrane topology of vitamin K-dependent GGCX
Five transmembrane domains of GGCX are labeled by Roman numerals and the boundary
residues noted. The single disulfide bond is between cysteines 99 and 450. Potential
glycosylation sites are marked by filled dots (•) and the residue number of the asparagines is
shown. Functional glycosylation sites identified in this paper are designated (Y).
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Table 1
GGCX mutants of asparagine to glutamine within the potential N-linked glycosylation sites
GGCX mutants Sites mutated
GGCX459 N459Q
GGCX627 N627Q, N459Q
GGCX550 N550Q, N627Q, N459Q
GGCX605 N605Q, N550Q, N627Q, N459Q
GGCX389 N389Q, N605Q, N550Q, N627Q, N459Q
GGCX525 N525Q, N605Q, N550Q, N627Q, N459Q
GGCX570 N570Q, N605Q, N550Q, N627Q, N459Q
GGCX389/525 N389Q, N525Q, N605Q, N550Q, N627Q, N459Q
GGCX570/525 N570Q, N525Q, N605Q, N550Q, N627Q, N459Q
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